The honest summary of psilocybin drug interactions is that we know far less than the topic’s importance deserves. The first systematic review of how psychedelics interact with psychiatric medications found only a handful of relevant human studies, almost all using full doses rather than microdoses. Within that thin evidence, a few signals stand out: lithium combined with a classic psychedelic is linked to seizures in case reports, MAOIs change how the body handles psilocin, and SSRIs appear to blunt psychedelic effects through receptor adaptation. Most other combinations are mechanistically plausible but barely studied, or rest on community reports. Three distinctions organize everything that follows — a dangerous mechanism is not a demonstrated rate of harm; absence of reports is not evidence of safety; and almost none of this evidence is microdose-specific. This page is not medical advice, and if you take any prescription medication the only responsible step is to talk to the clinician who prescribed it.
Why this is the hardest cluster to write honestly
Interactions are where the gap between what people want to know and what the evidence can support is widest. Someone deciding whether to microdose while on an antidepressant wants a clear yes or no. The literature offers neither. The first and still most thorough attempt to map the territory — a 2022 systematic review of drug interactions between psychiatric medications and psilocybin or MDMA — searched six decades of publications and found only a small number of human studies on psilocybin specifically, scattered across drug classes. [1] Systematic review Drug-drug interactions between psychiatric medications and MDMA or psilocybin: a systematic review doi:10.1007/s00213-022-06083-y That scarcity is the central fact of this cluster, and it cuts in an uncomfortable direction: it means most “is it safe to combine X with microdosing?” questions cannot be answered from evidence, only reasoned about from mechanism.
It is worth stating plainly what this cluster is and is not. It describes what the literature reports about combining psilocybin with other substances, and it flags genuine danger where danger has been documented. It does not provide combination or dosing instructions, it does not tell anyone it is safe to microdose alongside any medication, and it is emphatically not a substitute for a conversation with a prescribing clinician. Psilocybin is a controlled substance in most jurisdictions, and the safest interaction advice this library can give is to disclose any psychedelic interest to your doctor and never to alter a prescribed medication on your own.
Two ways drugs interact, and why the difference matters
Interactions are usually sorted into two kinds, and keeping them apart clarifies most of what follows. A pharmacokinetic interaction changes how much of a drug reaches its target — how it is absorbed, distributed, metabolized, or excreted. A pharmacodynamic interaction changes what happens at the target once the drug is there, often because two drugs act on the same receptor system.
For psilocybin, both routes are relevant. Psilocybin is a prodrug: the body converts it to psilocin, which is then cleared largely by glucuronidation and by the enzyme monoamine oxidase. [2] Peer-reviewed Metabolism of psilocybin and psilocin: clinical and forensic toxicological relevance doi:10.1080/03602532.2016.1278228 A drug that inhibits that clearance — an MAOI — is a pharmacokinetic interaction that can raise and prolong psilocin exposure. Psilocin’s effects, meanwhile, come from agonism at the serotonin 5-HT2A receptor, so any drug that occupies, blocks, or down-regulates that receptor is a pharmacodynamic interaction. [3] Peer-reviewed Psychedelics doi:10.1124/pr.115.011478 The detail behind both processes lives in how psilocybin becomes psilocin and the 5-HT2A mechanism.
| Type | What changes | Psilocybin example |
|---|---|---|
| Pharmacokinetic | How much active drug reaches the target | MAOIs slow psilocin breakdown, raising exposure |
| Pharmacodynamic | What happens at the target | SSRIs down-regulate 5-HT2A; antipsychotics block it |
The three distinctions this cluster holds
Because the evidence is thin, the way a finding is described matters as much as the finding itself. Three distinctions recur on every page.
A dangerous mechanism is not a measured rate of harm. Combining two serotonergic drugs gives a biological reason to worry about serotonin syndrome; it does not tell you how often that happens at a microdose, which in most cases is not known. [1] Systematic review Drug-drug interactions between psychiatric medications and MDMA or psilocybin: a systematic review doi:10.1007/s00213-022-06083-y Mechanistic plausibility earns caution, not a probability.
Absence of reports is not evidence of safety. Many combinations have simply never been studied or written up. “No known interaction” means not known, not known to be fine. The systematic review’s main conclusion was the scale of what is missing, not a clean bill of health for anything. [1] Systematic review Drug-drug interactions between psychiatric medications and MDMA or psilocybin: a systematic review doi:10.1007/s00213-022-06083-y
Almost none of this is microdose-specific. The receptor studies, the metabolism work, and the case reports overwhelmingly involve full perceptual doses. [4] Peer-reviewed Microdosing psychedelics: More questions than answers? An overview and suggestions for future research doi:10.1177/0269881119857204 A sub-perceptual dose might interact less — or the interaction might not scale down at all. For a serious signal like the lithium–seizure association, the absence of microdose data is a reason for caution rather than comfort.
Interaction evidence is not all the same kind of evidence
Some concerns in this cluster come from case reports, some from receptor pharmacology, some from general clinical knowledge, and some only from common co-use patterns. These do not carry the same weight, but none should be dismissed simply because microdose-specific trials are absent. It helps to sort interactions by the kind of concern they raise rather than by how alarming the drug name sounds.
| Category | What it means | Where it shows up here |
|---|---|---|
| Documented danger signal | Case reports or clinical evidence suggest serious harm is plausible enough to avoid | Lithium + classic psychedelics |
| Mechanistically high caution | Pharmacology strongly suggests elevated risk even where microdose incidence is unknown | MAOIs; serotonergic polypharmacy |
| Effect-blunting interaction | The medication may reduce or block effects rather than raise acute danger | SSRIs/SNRIs; antipsychotics |
| Additive impairment or load | Substances may stack cognitive, cardiovascular, anxiety, or sedation burden | Alcohol; cannabis; stimulants |
| Thin evidence / unknown | A common pairing with little direct study | Cannabis; stimulant combinations |
Sorting this way matters because it stops every page from sounding equally dangerous. It also keeps a recent and important counterweight in view: a 2025 scoping review of antidepressants taken alongside classic psychedelics concluded that, in the human studies available, concurrent antidepressant use was generally tolerated and did not raise the rate of serotonin syndrome — most visibly for psilocybin. [5] Systematic review Concomitant use of antidepressants and classic psychedelics: a scoping review doi:10.1177/02698811251368360 That finding does not license combining anything; it is a reminder that “high caution on mechanism” and “high measured rate of harm” are different claims.
A map of the cluster, from clearest danger to least studied
The sub-articles are ordered roughly by how well-grounded the concern is, not by how dangerous a combination sounds.
The lithium signal is the one hard caution in the set. An analysis of online experience reports found that a striking share of lithium-plus-psychedelic accounts involved seizures, while a comparison mood stabilizer showed none. [6] Observational Classic Psychedelic Coadministration with Lithium, but Not Lamotrigine, is Associated with Seizures: An Analysis of Online Psychedelic Experience Reports doi:10.1055/a-1524-2794 It is documented harm, treated in full in lithium and psilocybin.
MAOIs alter psilocin metabolism and serotonergic load, a pharmacokinetic and pharmacodynamic interaction at once; the caution is mechanistic and clinical rather than a counted incidence, and is covered in MAOIs and microdosing. The broader question of when serotonergic drugs together can tip into serotonin syndrome — tramadol, triptans, and the like — gets its own treatment, because the mechanism is real but the documented incidence at microdoses is essentially absent.
The most common real-world question concerns antidepressants. Here the better-supported finding is not danger but blunting: chronic SSRI and SNRI use appears to dampen or eliminate psychedelic effects, both during use and for a period after stopping. [7] Observational Attenuation of psilocybin mushroom effects during and after SSRI/SNRI antidepressant use doi:10.1177/02698811231179910 That story, and its important nuances, is in SSRIs, SNRIs and microdosing. Antipsychotics sit at the opposite mechanistic pole — as 5-HT2A blockers they are expected to block effects, the logic detailed in antipsychotics and microdosing.
The remaining pages — stimulants and ADHD medications, cannabis, and alcohol — cover combinations where the evidence is mostly community report and mechanistic reasoning, and where the honest verdict is individual variability rather than a clear rule.
For a single class-by-class reference that pulls the psychiatric-medication picture together — antidepressants, mood stabilizers, antipsychotics, sedatives, stimulants, and more, with dose context — see psychiatric medications and psilocybin.
- Pharmacokinetic vs pharmacodynamic
- Pharmacokinetic interactions change how much active drug reaches the target (e.g. MAOIs slowing psilocin clearance); pharmacodynamic interactions change what happens at the target (e.g. SSRIs down-regulating, antipsychotics blocking 5-HT2A). [2] Peer-reviewed Metabolism of psilocybin and psilocin: clinical and forensic toxicological relevance doi:10.1080/03602532.2016.1278228 [3] Peer-reviewed Psychedelics doi:10.1124/pr.115.011478
- Mechanism ≠ rate of harm
- A biologically plausible interaction is a reason for caution, not a measured probability of harm at microdose levels. [1] Systematic review Drug-drug interactions between psychiatric medications and MDMA or psilocybin: a systematic review doi:10.1007/s00213-022-06083-y
- Absence of reports ≠ safety
- Most combinations are unstudied; ‘no known interaction’ means not investigated, not shown to be safe. [1] Systematic review Drug-drug interactions between psychiatric medications and MDMA or psilocybin: a systematic review doi:10.1007/s00213-022-06083-y
- Full-dose evidence ≠ microdose evidence
- Nearly all interaction data come from full perceptual doses, so even the mechanisms may not translate to sub-perceptual amounts. [4] Peer-reviewed Microdosing psychedelics: More questions than answers? An overview and suggestions for future research doi:10.1177/0269881119857204
- The lithium exception
- Lithium plus a classic psychedelic is the cluster’s one documented-danger signal, on the basis of case reports of seizures. [6] Observational Classic Psychedelic Coadministration with Lithium, but Not Lamotrigine, is Associated with Seizures: An Analysis of Online Psychedelic Experience Reports doi:10.1055/a-1524-2794
Frequently asked questions
Does microdosing interact with my medication?
There is no blanket answer, and that is the honest starting point. A few interactions are well-grounded enough to take seriously: lithium combined with a classic psychedelic is linked to seizures in case reports, [6] Observational Classic Psychedelic Coadministration with Lithium, but Not Lamotrigine, is Associated with Seizures: An Analysis of Online Psychedelic Experience Reports doi:10.1055/a-1524-2794 and MAOIs alter how psilocin is handled by the body. [2] Peer-reviewed Metabolism of psilocybin and psilocin: clinical and forensic toxicological relevance doi:10.1080/03602532.2016.1278228 Most other combinations are either mechanistically plausible but barely studied or rest on community reports rather than controlled data. [1] Systematic review Drug-drug interactions between psychiatric medications and MDMA or psilocybin: a systematic review doi:10.1007/s00213-022-06083-y Almost all of the evidence concerns full psychedelic doses, not microdoses. This is not medical advice; if you take any prescription medication, the only responsible step is to discuss it with the clinician who prescribed it, and never to stop a prescribed medication on your own.
Is microdosing safe if there are no reports of a problem with my drug?
Absence of reports is not evidence of safety. Microdosing interactions have barely been studied in controlled settings, and the systematic review of psychiatric drug interactions with psilocybin found only a handful of relevant human studies. [1] Systematic review Drug-drug interactions between psychiatric medications and MDMA or psilocybin: a systematic review doi:10.1007/s00213-022-06083-y A combination that has not generated case reports may simply be one nobody has examined, not one that has been shown to be safe. Treat “no known interaction” as “not known”, not as “known to be fine”.
Is a 'dangerous interaction' the same as a 'proven' one?
No, and the distinction runs through this whole cluster. A dangerous-sounding mechanism — two serotonergic drugs together, for instance — describes a biological reason to be cautious, not a demonstrated rate of harm at microdoses. [1] Systematic review Drug-drug interactions between psychiatric medications and MDMA or psilocybin: a systematic review doi:10.1007/s00213-022-06083-y Conversely, the lithium signal is dangerous on the basis of case reports, which establish that harm has occurred but not how often or under what conditions. [6] Observational Classic Psychedelic Coadministration with Lithium, but Not Lamotrigine, is Associated with Seizures: An Analysis of Online Psychedelic Experience Reports doi:10.1055/a-1524-2794 Mechanism, case report, and controlled evidence answer different questions.
Do these interactions apply at microdose levels specifically?
Mostly the evidence does not address microdoses at all. The receptor pharmacology, the metabolism studies, and the case reports almost all involve full perceptual doses of psilocybin or LSD. [4] Peer-reviewed Microdosing psychedelics: More questions than answers? An overview and suggestions for future research doi:10.1177/0269881119857204 A microdose is, by definition, sub-perceptual, so it is plausible that some interactions are weaker or absent at that level — but plausible is not established, and a few risks, such as the lithium seizure signal, are serious enough that the lack of microdose-specific data is a reason for caution, not reassurance. [6] Observational Classic Psychedelic Coadministration with Lithium, but Not Lamotrigine, is Associated with Seizures: An Analysis of Online Psychedelic Experience Reports doi:10.1055/a-1524-2794
Should I stop or change my medication before microdosing?
No. Stopping, switching, or adjusting a prescribed medication carries its own serious risks — withdrawal, relapse, mood destabilization, or symptom rebound — independent of anything to do with psilocybin. Those decisions belong with the prescribing clinician who knows your history. This library describes what the research does and does not show; it is not a basis for changing treatment, and nothing here should be read as a reason to alter a prescribed medication on your own.